Cellectis SA (CLLS)
1.91
0.00 (0.00%)
USD |
NASDAQ |
Jun 25, 16:00
1.91
0.00 (0.00%)
After-Hours: 20:00
Cellectis Research and Development Expense (Annual): 87.65M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 87.65M |
| December 31, 2022 | 97.50M |
| December 31, 2021 | 117.84M |
| December 31, 2020 | 77.05M |
| December 31, 2019 | 92.04M |
| December 31, 2018 | 76.57M |
| December 31, 2017 | 79.23M |
| December 31, 2016 | 78.46M |
| Date | Value |
|---|---|
| December 31, 2015 | 58.15M |
| December 31, 2014 | 17.52M |
| December 31, 2013 | 24.64M |
| December 31, 2012 | 25.14M |
| December 31, 2011 | 15.95M |
| December 31, 2010 | 16.37M |
| December 31, 2009 | 11.42M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
77.05M
Minimum
2020
117.84M
Maximum
2021
94.42M
Average
92.04M
Median
2019
Research and Development Expense (Annual) Benchmarks
| Edap TMS SA | 7.538M |
| DBV Technologies SA | 60.22M |
| Genfit SA | 50.57M |
| Biophytis SA | 9.576M |
| Ascendis Pharma A/S | 447.61M |